18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 439-446

  Thomas, Alexandra ^a,b   Gingrich, Roger D ^a,b   Smith, Brian J ^c   Jacobus, Laura ^a   Ristow, Kay ^d   Allmer, Cristine ^d   Maurer, Matthew J ^d   Habermann, Thomas M ^d   Link, Brian K ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MAYO CLINIC ROCHESTER   (United States)

Author keywords

Diffuse large B cell lymphoma; FDG PET; Prognosis

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK; ADULT; AGED; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; REGISTER; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 77249171199     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903560198     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107: 265-276.
3. Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006;133:3-18.
4. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799-804. (Pubitemid 29441443)
5. Bangerter M, Moog F, Griesshammer M, Elsner K, Kotzerke J, Heimpel H. Role for whole body FDG-PET imaging in predicting relapse in patients with residual masses after treatment. Radiography 1999;5:155-163.
6. Cremerius U, Fabry U, Kroll U. Clinical value of FDG PET for therapy monitoring of malignant lymphoma - results of a retrospective study in 72 patients. Nuklearmedizin 1999;38: 24-30.
7. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001;86:266-273.
8. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin lymphoma by integrated International Workshop Criteria and fluorine-18- fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-4661.
9. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin lymphoma. Br J Haematol 2001; 115:793-800. (Pubitemid 34042895)
10. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419.
11. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-728.
12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in clinical oncology: non-Hodgkin lymphomas, ed V.3.2008. Available at http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp, accessed 23 November 2009.
13. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25: 571-578.
14. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
15. Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol 1990;8:1598.
16. A predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
17. Sachs S, Bilfinger TV. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest 2005;128:698-703.
18. Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun 2007;28:273-280.
19. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography (PET) in diffuse large B-cell lymphoma: independent expert nuclear medicine evaluation of ECOG 3404. Blood 2008;112(Suppl. 1): (page 145).
20. Cashen A, Dehdashti F, Luo J, Bartlett N. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLCL). Blood 2008;112(Suppl. 1): (page 144).
21. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-1787.
22. Trneny M, Belohlavek O, Koren J, Pytlik R, Salkova J, Klener P. [The outcome of whole-body FDG-PET examination predicts the future of patients with diffuse largecell lymphoma in the use of both intermediary staging and at the end of standard chemotherapy]. Vnitr Lek 2007;53:936-941.
23. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752.
24. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol 2002;13:1356-1363.
25. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16: 1514-1523.
26. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486-491.